← Back to Search

Behavioural Intervention

Genetic Testing Access for Cancer

N/A

Waitlist Available

Led By Charite Ricker

Research Sponsored by University of Southern California

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age > 18 years old

Be older than 18 years old

Must not have

Patients who cannot provide informed consent

Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial compares how patients with cancer receive information about genetic testing either from a computer-generated character or from a human genetics healthcare provider. Many patients with cancer are recommended for genetic testing, but some don't

Who is the study for?

This trial is for cancer patients who might benefit from genetic testing but have limited access to it, especially those in racial/ethnic minorities or living in rural areas. Participants should be treated at hospitals with few genetics services and must speak either English or Spanish.

What is being tested?

The study compares two ways of educating about genetic testing: one uses a computer-generated character (PERLA) and the other uses human healthcare providers. It aims to see if PERLA can improve access to genetic testing for cancer patients.

What are the potential side effects?

Since this trial focuses on educational interventions rather than medical treatments, traditional physical side effects are not expected. However, participants may experience emotional or psychological responses to the information provided.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am unable to give informed consent.

Select...

I meet the study's requirements but do not speak English or Spanish.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of participants who receive genetic testing

Secondary study objectives

Patient-reported outcomes

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention Phase Arm A (PERLA)Experimental Treatment5 Interventions

Patients receive access to PERLA comprising pre-test genetics education and standard post-test provider-based genetic counseling over 20-60 minutes. .

Group II: Intervention Phase Arm B (usual care)Active Control3 Interventions

Patients receive access to usual care pre- and post-test provider-based genetic counseling.

0 / 3Eligibility criteria met